InMode is a profitable medical device company that sells radiofrequency-based aesthetic and surgical systems, including Morpheus8; it has no drug pipeline.
InMode's case rests on a sale or recovery in its device business, with potential capital returns also under consideration. The special committee remains active, but no party has agreed to an NDA in the current process. The CEO-led group's proposal expired without agreement. Second-quarter revenue was flat at $95.6 million, while GAAP operating margin fell to 13% from 24%. Cash, marketable securities and short-term bank deposits totaled $501.1 million as of June 30, 2026.
Thesis checklist
2 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: The special committee agrees a sale at a premium
Does the committee recommend a sale at a premium with credible execution terms and shareholder support?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
InMode's sale process lacks NDAs as device margins remain pressured
Profitable med-device franchisor with $537M cash trades through a contested go-private bid while revenue stabilizes — governance chaos and margin compression are the deciding factors
Cash-rich aesthetics device maker navigating margin erosion and a CEO-led buyout bid — whether the $16.20 offer clears or collapses defines the near-term outcome
InMode's investment case rests on whether margin recovery and capital returns can offset a medical-device revenue cycle inflection amid leadership turnover and failed M&A
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.